Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
| 0.6608 | |
| 0.705 | |
| - | |
| 0.705 | |
| 0.6475 | |
| 0.51-1.94 | |
| 17 022 K | |
| 25 081 K | |
| 0 | |
| -0.32 | |
| 0.025 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Sensei Biotherapeutics - Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in specific tumor types - - Multiple clinical mil...
Sensei Biotherapeutics Inc (NASDAQ:SNSE) reported a strong balance sheet with a cash runway into the second half of 2025. The company's R&D expenses decreased to $3.8 million in Q3 2023, compared to $...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
